New IVIG treatment aims to boost platelets in ITP patients
NCT ID NCT07233213
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a human immunoglobulin (IVIG) given intravenously for 5 days to adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risk. The study will enroll 36 participants in Turkey to see if the treatment safely raises platelet counts within a week. It is an open-label, single-arm study, meaning everyone gets the drug and there is no placebo group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- human immunoglobulin (IVIG) given intravenously
- What this could lead to
- If successful, this could provide a safe and effective short-term treatment to raise platelet counts and reduce bleeding risk in people with chronic ITP.
- What could go wrong
- This is a small, single-arm Phase 3 trial with no placebo group, so results may be less definitive. IVIG can cause side effects like headache, fever, or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Adana City Education and Research Hospital, Hematology Department
RECRUITINGAdana, Yüreğir, 01230, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Antalya Training and Research Hospital
RECRUITINGAntalya, Muratpaşa, 07100, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi
RECRUITINGAnkara, Yenimahalle, 06200, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Erciyes University Hematology Hospital
RECRUITINGKayseri, Melikgazi, 38039, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Gaziantep University Şahinbey Training and Research Hospital
RECRUITINGGaziantep, Şehitkamil, 27310, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hacettepe University Faculty of Medicine
RECRUITINGAnkara, Altındağ, 06230, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
VM Medical Park Mersin
RECRUITINGMersin, Mezitli, 33200, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
İnönü University Turgut Ozal Medical Center Training and Research Hospital
RECRUITINGMalatya, Battalgazi, 44280, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
İstanbul University, Istanbul Faculty of Medicine
RECRUITINGIstanbul, Fatih, 34093, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental injection aims to boost platelets in chronic blood disorder
- New combo therapy aims to boost platelets in immune disorder
- New hope for kids with ITP: drug combo aims to control bleeding
- Can a vitamin a drug boost platelets in Hard-to-Treat ITP?
- Real-World study to track Eltrombopag's effectiveness in ITP patients
- New pill could help adults with low platelet disorder